HYDROCHLOROTHIAZIDE W/ RESERPINE
Clinical safety rating: safe
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and blood pressure. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
| Metabolism | Hydrochlorothiazide is not extensively metabolized; it is primarily excreted unchanged in urine. Reserpine is extensively metabolized in the liver via hydrolysis and conjugation to inactive metabolites; the specific CYP enzymes involved are not well characterized. |
| Excretion | Hydrochlorothiazide: primarily renal (≥95% unchanged); Reserpine: renal (30%) and fecal (60%) as metabolites. |
| Half-life | Hydrochlorothiazide: 6–15 hours (mean 10 hours), prolonged in renal impairment; Reserpine: 50–100 hours (due to slow release from adrenergic neurons). |
| Protein binding | Hydrochlorothiazide: 40–68% (primarily albumin); Reserpine: >95% (albumin and other proteins). |
| Volume of Distribution | Hydrochlorothiazide: 3–4 L/kg (extensive tissue distribution); Reserpine: 10–25 L/kg (large due to high lipophilicity and tissue binding). |
| Bioavailability | Hydrochlorothiazide: 65–75% (oral); Reserpine: 30–50% (oral, variable due to first-pass metabolism). |
| Onset of Action | Hydrochlorothiazide: oral, 2 hours (diuresis); Reserpine: oral, 3–6 days (antihypertensive effect due to gradual catecholamine depletion). |
| Duration of Action | Hydrochlorothiazide: 6–12 hours (diuresis); Reserpine: 1–6 weeks (antihypertensive effect persists after cessation). |
25 mg/0.125 mg orally once daily initially, then titrate to 50 mg/0.25 mg once daily if needed.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in anuria or GFR <30 mL/min. For GFR 30-50 mL/min: avoid use or reduce dose cautiously. |
| Liver impairment | Use with caution in severe hepatic impairment (Child-Pugh class C); may precipitate hepatic coma. Consider dose reduction. |
| Pediatric use | Not recommended in children due to reserpine risks. Alternative agents preferred. |
| Geriatric use | Initiate at lowest dose (25 mg/0.125 mg daily) due to increased sensitivity to hypotension and electrolyte disturbances. Monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.
| FDA category | Animal |
| Breastfeeding | Both components are excreted in breast milk. Hydrochlorothiazide appears at low levels (M/P ratio ~0.05-0.5). Reserpine is present with potential for significant infant exposure. Use is contraindicated due to risk of neonatal hypotension, bradycardia, and electrolyte imbalance. |
| Teratogenic Risk | First trimester: Reserpine is associated with increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies, based on animal studies and limited human data. Second and third trimesters: Hydrochlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Reserpine may cause neonatal respiratory depression and bradycardia. Avoid use during pregnancy. |
■ FDA Black Box Warning
Risk of depression: Reserpine may cause severe depression, including suicidal ideation, especially in patients with a history of depression. Discontinue at first signs of despondency, early morning insomnia, loss of appetite, impotence, or self-deprecation.
| Common Effects | Depression |
| Serious Effects |
Hypersensitivity to hydrochlorothiazide, sulfonamides (hydrochlorothiazide is a sulfonamide derivative), or reserpine; anuria; history of depression, active peptic ulcer, or ulcerative colitis; concurrent electroconvulsive therapy (ECT); pheochromocytoma.
| Precautions | Reserpine: Risk of depression, peptic ulcer (may exacerbate), pancreatitis, Parkinsonism (may worsen), and hypotension (especially orthostatic). Hydrochlorothiazide: Electrolyte disturbances (hypokalemia, hyponatremia, hypomagnesemia), volume depletion, hyperuricemia, hypercalcemia, azotemia, and hypersensitivity reactions (including anaphylaxis and photosensitivity). Avoid abrupt withdrawal of reserpine due to rebound hypertension. Monitor electrolytes and mental status. |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor blood pressure, serum electrolytes (especially potassium, sodium), renal function, and signs of hypokalemia. Fetal/neonatal: Monitor for jaundice, thrombocytopenia, electrolyte disturbances, bradycardia, and respiratory depression. |
| Fertility Effects | Reserpine may impair fertility by decreasing libido and causing menstrual irregularities. Hydrochlorothiazide has no known direct effect on fertility. Overall, combination may reduce fertility potential. |